Literature DB >> 18216112

E4Orf6-E1B-55k-dependent degradation of de novo-generated adeno-associated virus type 5 Rep52 and capsid proteins employs a cullin 5-containing E3 ligase complex.

Ramnath Nayak1, K David Farris, David J Pintel.   

Abstract

Degradation of de novo-generated adeno-associated virus type 5 (AAV5) Rep52 and capsid proteins is part of the limited target specificity displayed by adenovirus type 5 E4Orf6-E1B-55k as part of a cullin 5-containing E3 ligase complex. Both Rep and capsid proteins can be found in the ligase complex, and their presence is dependent on interaction between E4Orf6 and elongins B and C. Degradation of AAV5 proteins can be inhibited by a dominant-negative ubiquitin that prevents chain elongation or by small interfering RNA directed against cullin 5.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18216112      PMCID: PMC2268487          DOI: 10.1128/JVI.02532-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  16 in total

1.  The NS2 protein generated by the parvovirus minute virus of mice is degraded by the proteasome in a manner independent of ubiquitin chain elongation or activation.

Authors:  C L Miller; D J Pintel
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

2.  Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex.

Authors:  E Querido; P Blanchette; Q Yan; T Kamura; M Morrison; D Boivin; W G Kaelin; R C Conaway; J W Conaway; P E Branton
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

3.  The adenovirus type 5 E1B-55K oncoprotein actively shuttles in virus-infected cells, whereas transport of E4orf6 is mediated by a CRM1-independent mechanism.

Authors:  T Dosch; F Horn; G Schneider; F Krätzer; T Dobner; J Hauber; R H Stauber
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53.

Authors:  Paola Blanchette; Chi Ying Cheng; Qin Yan; Gary Ketner; David A Ornelles; Thomas Dobner; Ronald C Conaway; Joan Weliky Conaway; Philip E Branton
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

5.  Adenovirus ubiquitin-protein ligase stimulates viral late mRNA nuclear export.

Authors:  Jennifer L Woo; Arnold J Berk
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Molecular characterization of caprine adeno-associated virus (AAV-Go.1) reveals striking similarity to human AAV5.

Authors:  Jianming Qiu; Fang Cheng; David Pintel
Journal:  Virology       Date:  2006-08-22       Impact factor: 3.616

7.  Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination.

Authors:  R J Sheaff; J D Singer; J Swanger; M Smitherman; J M Roberts; B E Clurman
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

8.  Positive and negative effects of adenovirus type 5 helper functions on adeno-associated virus type 5 (AAV5) protein accumulation govern AAV5 virus production.

Authors:  Ramnath Nayak; David J Pintel
Journal:  J Virol       Date:  2006-12-13       Impact factor: 5.103

9.  Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex.

Authors:  Travis H Stracker; Christian T Carson; Matthew D Weitzman
Journal:  Nature       Date:  2002-07-18       Impact factor: 49.962

10.  Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery.

Authors:  Josephine N Harada; Anna Shevchenko; Andrej Shevchenko; David C Pallas; Arnold J Berk
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  12 in total

1.  The E4orf6/E1B55K E3 ubiquitin ligase complexes of human adenoviruses exhibit heterogeneity in composition and substrate specificity.

Authors:  Chi Ying Cheng; Timra Gilson; Frédéric Dallaire; Gary Ketner; Philip E Branton; Paola Blanchette
Journal:  J Virol       Date:  2010-11-10       Impact factor: 5.103

2.  Role of E1B55K in E4orf6/E1B55K E3 ligase complexes formed by different human adenovirus serotypes.

Authors:  Chi Ying Cheng; Timra Gilson; Peter Wimmer; Sabrina Schreiner; Gary Ketner; Thomas Dobner; Philip E Branton; Paola Blanchette
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

3.  The large Rep protein of adeno-associated virus type 2 is polyubiquitinated.

Authors:  Loretta Sukhu; David Pintel
Journal:  J Gen Virol       Date:  2011-08-24       Impact factor: 3.891

4.  ICP0 dismantles microtubule networks in herpes simplex virus-infected cells.

Authors:  Mingyu Liu; Edward E Schmidt; William P Halford
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

5.  Adeno-associated virus small rep proteins are modified with at least two types of polyubiquitination.

Authors:  K David Farris; Olufemi Fasina; Loretta Sukhu; Long Li; David J Pintel
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

6.  Adeno-associated virus type 5 utilizes alternative translation initiation to encode a small Rep40-like protein.

Authors:  K David Farris; David J Pintel
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

7.  E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus.

Authors:  Michael A Thomas; Robin S Broughton; Felicia D Goodrum; David A Ornelles
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

8.  Characterization of the nonstructural proteins of the bocavirus minute virus of canines.

Authors:  Loretta Sukhu; Olufemi Fasina; Lisa Burger; Ayushi Rai; Jianming Qiu; David J Pintel
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

9.  Adeno-associated virus: a key to the human genome?

Authors:  Els Henckaerts; R Michael Linden
Journal:  Future Virol       Date:  2010-09-01       Impact factor: 1.831

10.  The Role of Elongin BC-Containing Ubiquitin Ligases.

Authors:  Fumihiko Okumura; Mariko Matsuzaki; Kunio Nakatsukasa; Takumi Kamura
Journal:  Front Oncol       Date:  2012-02-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.